Drug Profile
CP 166907
Latest Information Update: 21 Mar 2000
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 21 Mar 2000 No-Development-Reported for Asthma in USA (Unknown route)
- 03 Jun 1998 Preclinical development for Asthma in USA (Unknown route)
- 08 May 1998 New profile